Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IDT Biologika, a biotechnological manufacturer of vaccines and pharmaceuticals, will invest approximately EUR85m in new high-tech production plants and pharmaceutical infrastructure by the end of 2012 in Germany.
Subscribe to our email newsletter
IDT Biologika plans to build a new frozen storage area, a filling building for vaccines and several special warehouses.
Additionally, the company also intends to expand research laboratory alongside general capacity expansion.
IDT Biologika CEO Ralf Pfirmann said with their investment programme which is now beginning, IDT has also been able to rely on the swiftness and flexibility of the processing of all official proceedings – a competitive advantage which the customers value greatly.
"Our new plants will enable us to offer biotechnological products on an international parquet more widely than before at the highest level," Pfirmann said.